Where can I buy amivantamab in the country?

Evantumumab (amivantamab) is an innovative targeted therapy drug that has been launched in China and is mainly used to treat non-small cell lung cancer (NSCLC) with EGFR mutations or c-MET amplification. Although it has been approved to enter the Chinese market, it has not yet been included in the scope of national medical insurance reimbursement. Therefore, patients still need to pay for it out of pocket.

In China, the main purchase channels for evantumumab are hospital pharmacies and some formal drug import channels. Currently, the original drug of this drug is produced by JANSSEN BIOTECH and distributed through formal channels. Depending on the patient's needs, it can be purchased through the hospital pharmacy and is usually recommended by a doctor during treatment in a cancer specialist or oncology department.

Based on the specifications of the drug and the market situation, the selling price of evantumumab in the Chinese market is approximately more than RMB 7,000 per box of 350mg. The price of the imported version of the Hong Kong version of the drug is usually around RMB 8,000, and this price may change slightly based on exchange rate fluctuations. It should be noted that although evantumumab is already on the market in China, there is currently no generic version available, so the price is higher.

For patients who wish to purchase evantumumab, in addition to purchasing it through hospital pharmacies, some patients also purchase it through cross-border e-commerce platforms or overseas medical channels. Especially in regions such as Hong Kong, there may be more convenient purchasing channels. However, when choosing these channels, patients need to ensure that they are purchasing drugs from regular channels to avoid buying fake and shoddy products.

In overseas markets, especially Europe and the United States, the price of evantumumab is higher than domestically, and the price of each box may reach around RMB 20,000. The specific price is affected by exchange rate fluctuations. If the patient has the conditions, it may be possible to save money by considering direct import from overseas through an international drug agent or purchasing channel, but this also involves some legal and logistical challenges.

Reference materials:https://www.rybrevant.com/